NEW YORK, Sept. 13 /PRNewswire-FirstCall/ -- Pfizer Inc said today it has received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.
Pfizer said that it will be reviewing its submission with the FDA and considering various possible courses of action.
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888.Pfizer Inc
CONTACT: Mariann Caprino of Pfizer Inc, +1-212-733-4554